KTTAPasithea Therapeutics Corp.

Nasdaq pasithea.com


$ 7.56 $ 0.29 (4.17 %)    

Friday, 12-Apr-2024 10:26:02 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 7.24
$ 7.56
$ 0.00 x 0
$ 0.00 x 0
$ 7.56 - $ 7.56
$ 5.25 - $ 17.40
221
na
7.55M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-18-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pasithea-therapeutics-announces-the-first-cohort-has-completed-the-initial-dosing-in-its-phase-1-trial-evaluating-pas-004-in-ras-nf1-and-raf-mutated-cancers

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company...

 pasithea-therapeutics-announces-opening-of-enrollment-in-the-us-for-its-phase-1-trial-of-pas-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and prelimi...

 pasithea-therapeutics-announces-invention-of-crystalline-form-of-pas-004-establishes-strengthened-intellectual-property-position

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Fil...

 pasithea-therapeutics-corp-announces-1-for-20-reverse-stock-split-anticipates-common-stock-will-begin-trading-on-a-reverse-stock-split-adjusted-basis-at-market-open-on-january-2-2024

- SEC Filing On December 28, 2023, Pasithea Therapeutics Corp. (the "Company") filed a Certificate of Amendment to the ...

 nasdaq-edges-higher-macys-shares-jump

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow tra...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 dow-surges-100-points-cogent-biosciences-shares-plunge

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow trad...

 us-stocks-mixed-cigna-shares-spike-higher

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 20 points on Monday. Following the market op...

 neurology-focused-pasithea-therapeutics-stock-soars-over-150-today---heres-why

Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor effic...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION